Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
At present 18 per cent of the local pharmaceutical market is under government's price control
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
